331 related articles for article (PubMed ID: 32224190)
1. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile.
Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K
J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190
[TBL] [Abstract][Full Text] [Related]
2. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
3. The effect of berberine chloride and/or its combination with vancomycin on the growth, biofilm formation, and motility of Clostridioides difficile.
Wultańska D; Piotrowski M; Pituch H
Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1391-1399. PubMed ID: 32140903
[TBL] [Abstract][Full Text] [Related]
4. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
Takeda S; Miki T
Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
[TBL] [Abstract][Full Text] [Related]
5. High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates.
Tijerina-Rodríguez L; Villarreal-Treviño L; Baines SD; Morfín-Otero R; Camacho-Ortíz A; Flores-Treviño S; Maldonado-Garza H; Rodríguez-Noriega E; Garza-González E
PLoS One; 2019; 14(7):e0220671. PubMed ID: 31365590
[TBL] [Abstract][Full Text] [Related]
6. Fidaxomicin for the treatment of
Skinner AM; Scardina T; Kociolek LK
Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.
James GA; Chesnel L; Boegli L; deLancey Pulcini E; Fisher S; Stewart PS
J Antimicrob Chemother; 2018 Jan; 73(1):102-108. PubMed ID: 29029221
[TBL] [Abstract][Full Text] [Related]
8. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores.
Bassères E; Endres BT; Montes-Bravo N; Pérez-Soto N; Rashid T; Lancaster C; Begum K; Alam MJ; Paredes-Sabja D; Garey KW
Anaerobe; 2021 Jun; 69():102352. PubMed ID: 33640461
[TBL] [Abstract][Full Text] [Related]
9. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.
Yamaguchi T; Konishi H; Aoki K; Ishii Y; Chono K; Tateda K
J Infect Chemother; 2020 May; 26(5):483-491. PubMed ID: 32165071
[TBL] [Abstract][Full Text] [Related]
10. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
11. Diversity of Circulating
Martínez-Meléndez A; Tijerina-Rodríguez L; Collins N; Baines SD; Morfin-Otero R; Camacho-Ortíz A; Villarreal-Treviño L; Garza-González E
Microb Drug Resist; 2021 Dec; 27(12):1672-1676. PubMed ID: 34037477
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.
Schwanbeck J; Riedel T; Laukien F; Schober I; Oehmig I; Zimmermann O; Overmann J; Groß U; Zautner AE; Bohne W
J Antimicrob Chemother; 2019 Jan; 74(1):6-10. PubMed ID: 30247587
[TBL] [Abstract][Full Text] [Related]
13. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.
Cao X; Boyaci H; Chen J; Bao Y; Landick R; Campbell EA
Nature; 2022 Apr; 604(7906):541-545. PubMed ID: 35388215
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
15. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile.
Ðapa T; Leuzzi R; Ng YK; Baban ST; Adamo R; Kuehne SA; Scarselli M; Minton NP; Serruto D; Unnikrishnan M
J Bacteriol; 2013 Feb; 195(3):545-55. PubMed ID: 23175653
[TBL] [Abstract][Full Text] [Related]
16. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection.
Abutaleb NS; Seleem MN
Sci Rep; 2020 May; 10(1):7701. PubMed ID: 32382070
[TBL] [Abstract][Full Text] [Related]
17. U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.
Thorpe CM; McDermott LA; Tran MK; Chang J; Jenkins SG; Goldstein EJC; Patel R; Forbes BA; Johnson S; Gerding DN; Snydman DR
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085514
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
Sullivan KM; Spooner LM
Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
[TBL] [Abstract][Full Text] [Related]
19. Is shorter also better in the treatment of Clostridioides difficile infection?
Duricek M; Halmova K; Krutova M; Sykorova B; Benes J
J Antimicrob Chemother; 2024 Jun; 79(6):1413-1417. PubMed ID: 38661207
[TBL] [Abstract][Full Text] [Related]
20. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
